INTRODUCTION
The increasing global prevalence of the metabolic syndrome (MetS), which groups obesity, hyperglycemia, dyslipidemia, and hypertension, is a major worldwide public health problem. Nonalcoholic fatty liver disease (NAFLD) is often considered the hepatic manifestation of MetS and is closely related to many of its features. NAFLD comprises a hepatic spectrum ranging from simple hepatic steatosis or nonalcoholic fatty liver (NAFL), characterized by abnormal triglyceride accumulation in hepatocytes, which can progress to nonalcoholic steatohepatitis (NASH). While NAFL is generally considered benign, NASH combines NAFL with elements of hepatic tissue injury including evidence of inflammation and hepatocyte ballooning with or without fibrosis. NAFLD is an independent risk factor for cirrhosis, hepatocellular carcinoma, cardiovascular disease, and mortality. Importantly, NAFLD is strongly and bidirectionally associated with obesity, insulin resistance, and type 2 diabetes (T2D) [1
There are several unmet research needs in the field of NAFLD. The natural history of NAFLD is not entirely understood and no pharmacological therapies exist for its treatment. For example, NAFL can be diagnosed with noninvasive imaging techniques,
BILE ACID PHYSIOLOGY
Bile acids are cholesterol-derived molecules synthesized exclusively in hepatocytes via two pathways. The classical pathway produces the majority of bile acids. It is initiated by cytochrome P450 (CYP) cholesterol 7a-hydroxylase (CYP7A1), whose activity correlates with plasma levels of 7a-hydroxy-4-cholesten-3-one (C4). The alternative pathway, initiated by CYP 27a-hydroxylase (CYP27A1), synthesizes the remaining minor bile acid fraction. These pathways produce the primary bile acids cholic acid (CA), chenodeoxycholic acid (CDCA), and hyocholic acid (HCA) in humans. Notably, CA is a 12a-hydroxylated bile acid, synthetized by the CYP 12a-hydroxylase (CYP8B1), which is indirectly regulated by insulin signaling via forkhead box protein O1 (FoxO1). Thus, the 12a-hydroxylated:non-12a-hydroxylated bile acid ratio reflects the activity of CYP8B1 and is a marker of hepatic insulin sensitivity of the bile acid synthesis pathway. Upon synthesis, bile acids are conjugated to glycine or taurine (the proportion being essentially determined by dietary intake), secreted into bile, and released in the duodenum postprandially to facilitate dietary fat solubilization and absorption. In the gut, microbiota deconjugate and transform primary bile acids into secondary bile acids:CA into deoxycholic acid (also a 12a-hydroxylated bile acid), CDCA into ursodeoxycholic acid (UDCA) and lithocholic acid (LCA), and HCA into hyodeoxycholic acid. Approximately 95% of bile acids are recaptured in the ileum and return to the liver via the portal vein to be reconjugated and resecreted into bile. A minor fraction of portal bile acids escapes hepatic reuptake and reach the systemic circulation, hence potentially allowing signaling actions in peripheral organs [5 & ]. However, it should be noted that circulating plasma bile acids do not necessarily reflect the composition of the portal, intrahepatic, biliary, or intestinal bile acid pools.
Apart from their role in dietary lipid solubilization, bile acids are natural ligands of the farnesoid X receptor (FXR) and the Takeda G-protein-coupled receptor (TGR5), through which bile acids regulate their own synthesis, as well as glucose, lipid and energy homeostasis, inflammation, hepatic fibrosis, and modulate reparative activity (reviewed in [5 & ]). Importantly, not all bile acids activate FXR (CDCA > DCA > CA > LCA) and TGR5 (LCA > D-DCA > CDCA > CA) with the same affinity or potency. Hence, qualitative alterations of the bile acid pool composition, in addition to quantitative changes in total bile acids, could modulate the activity of their receptors and hence impact metabolism.
Bile acid-FXR signaling in enterocytes stimulates the secretion of fibroblast growth factor 19 (FGF19) into portal venous blood, which then activates FGFR4/b-Klotho in the liver. Through this mechanism, FGF19 suppresses CYP7A1, thereby decreasing bile acid synthesis via the classical pathway, and also regulates hepatic carbohydrate and lipid metabolism. Interestingly, plasma FGF19 (a biomarker of intestinal FXR activation) is decreased in the metabolic syndrome, suggesting that it could be implicated in the pathogenesis of NAFLD [6, 7] . Considering many interactions between diet, insulin signaling, and bile acid metabolism, it appears logical that alterations in circulating bile acids could be markers of, or even actors in, the pathophysiology of the metabolic processes that they modulate.
BILE ACIDS IN OBESITY, INSULIN RESISTANCE, AND TYPE 2 DIABETES
The effect of obesity on bile acid metabolism is not entirely clear. BMI has been reported to positively
KEY POINTS
Bile acid changes have been associated with obesity, insulin resistance, and T2D, common comorbidities of NAFLD.
Discordant results on plasma bile acid alterations in NAFLD patients have been reported.
The intricate relationship between NAFLD, obesity, insulin resistance, and T2D renders difficult the establishment of clear and independent associations between bile acid alterations and these individual diseases.
Further studies with appropriate matching or adjustment for potential confounding factors are necessary to determine which of these diseases drive the alterations in bile acid metabolism in NAFLD.
Bile acid signaling pathways remain attractive candidates for the treatment of NAFLD, but whether bile acids are a driving force in the pathogenesis and progression of NAFLD or just innocuous bystanders remains undetermined.
correlate with fasting bile acids [8] but negatively with postprandial bile acids [9] . Other studies have reported either no changes [10] [11] [12] or increased concentrations of CA [13] in fasting plasma bile acids, and no changes [10] or decreased glyco-conjugated bile acids [11] in postprandial plasma of obese individuals. There is also evidence that the normal meal-induced bile acid increase in plasma bile acids is suppressed with obesity [12, 14] . Similarly, insulin infusion during an euglycemic hyperinsulinemic clamp decreased serum bile acids in lean but not in obese patients [12] . Fasting plasma C4 levels were higher in obese patients in two different studies [12, 15 && ], suggesting increased bile acid biosynthesis. Expression of the canalicular (BSEP) and sinusoidal (NTCP) bile acid transporter mRNA levels were negatively correlated with BMI [12] . Although there is a large heterogeneity between the reported results, possibly because of the known large inter and intraindividual variability in bile acids and the diurnal variations of bile acids in humans [15 && ], overall fasting plasma bile acids appear elevated, but the postprandial increase is lower in obese individuals.
A parameter confounding these studies may be related to differences in the level of insulin resistance among the studied patient populations. Studies analyzing bile acid changes in insulin resistant, but not diabetic patients have reported higher fasting total and 12a-hydroxylated bile acids [16 & ]. Mechanistic studies in insulin-resistant mice suggest that impaired insulin-mediated repression of FoxO1 results in higher 12a-hydroxylase CYP8B1 expression [17] . Moreover, insulin resistance was associated with increased total bile acid concentrations [18, 19] , fasting tauro-conjugated bile acids [20] , CDCA, CA, DCA [13] , and glyco-chenodeoxycholic acid (GCDCA) [21] . Some studies in overtly T2D patients have reported no changes in fasting [9, 22] or postprandial [9, 23] bile acids compared with controls, whereas other studies have reported either increased fasting [7,16 & ,24] and postprandial [24] total bile acid concentrations, increased fasting DCA [9, 13, 25] , tauro-chenodeoxycholic acid, tauro-deoxycholic acid, and tauro-ursodeoxycholic acid (TUDCA) [20] , or decreased CA and HCA [25] . Bile acid levels were not modified by intensive insulin treatment in diabetic patients [20] .
The mechanisms underlying the quantitative and qualitative modifications in bile acids in the metabolic syndrome are not fully elucidated. Apart from the previously described alterations of the insulin receptor-protein kinase b (Akt)-FoxO1 signaling pathway impacting bile acid synthesis in insulin resistance, dysbiosis (occurring in metabolic disorders) could modify bile acid deconjugation, secondary bile acid synthesis, and modulate the bile acid pool composition [5 & ]. Another mechanism implies the enterohepatic cross-talk via intestinally FXR-induced FGF19. Indeed, FGF19 levels correlate positively with total bile acid concentrations [10, 24] and negatively with plasma C4 [10, 26] . Interestingly, FGF19 is lower in T2D and obese patients and correlates negatively with BMI [10, 27] and glycated hemoglobin (HbA1c) [27] . However, these changes in FGF19 in T2D patients [9, 24] or its correlation with MetS components [20] are not universally observed. Importantly, differences in control populations and the degree of insulin resistance or T2D severity are potential confounding factors between these studies and are not always well reported nor well characterized.
In conclusion, although not all reported data are entirely consistent, it is clear that bile acid metabolism alterations occur in obese and/or insulin-resistant humans (summarized in Table 1 ). However, it remains undetermined whether bile acids are innocent bystanders or if they participate to the pathophysiology of these diseases.
BILE ACIDS AND NONALCOHOLIC FATTY LIVER DISEASE
Given that bile acid accumulation in hepatocytes is cytotoxic in intrahepatic cholestatic liver diseases, it is conceivable that bile acids could be altered in NAFLD also and that their accumulation in NASH patients could favor progression of the disease. Furthermore, hepatic necroinflammatory lesions in NAFLD may alter the anatomy of liver zonation. Since the liver is the sole site of bile acid synthesis and as bile acid synthesis is zonated in physiological conditions, altered bile acid metabolism could occur in a setting of pathologically altered liver zonation. Indeed, treatment of NASH with the FXR agonist obeticholic acid [28 && ] or with the FGF19 analog NGM282 [29 && ] improved several NAFLD histological features. Therefore, several groups have studied whether NAFLD patients present bile acid profile alterations (summarized in Table 2 ).
Fasting plasma bile acids were reported to be higher in NASH patients because of increased primary [30 && ] and conjugated bile acid species [30 && ,31,32] . Similar changes were also observed in NAFL patients [31] . Moreover, histological lesions of NASH have been associated with bile acid alterations [i.e. associations of high plasma glyco-cholic acid (GCA) [ Bile acid changes in NAFLD and metabolic syndrome Chá vez-Talavera et al. Bile acid changes in NAFLD and metabolic syndrome Chá vez-Talavera et al. [32] , as well as increased fecal bile acid loss, which positively correlated with NAS and associated with decreased proportions of the gut microbiota phylum Bacteroidetes [35] . Furthermore, hepatic tissue-extracted bile acids were reported to be altered in NASH and NAFL patients resulting in qualitative changes in hepatic bile acid content, although inconsistent results were obtained between both studies [36, 37] . Such results should be taken with caution, as bile acids were extracted from whole hepatic tissue, preventing discrimination between blood, biliary, and intrahepatocyte bile acid concentrations.
The expression of hepatic bile acid metabolism genes has also been studied in livers from NASH patients. Both increased [38] and decreased [36] CYP27A1 mRNA levels were reported, in addition to increased CYP7B1 gene and protein levels [36] . These results suggest possible modifications in the alternative bile acid synthesis pathway. Furthermore, increased expression of the gene encoding CYP7A1 [30 && ,38,39 & ] suggests that the classical bile acid synthesis pathway may also be activated. FGF19 levels, which regulate bile acid synthesis, have been reported as decreased [38] Table 2 .
We recently compared bile acid metabolism parameters in NASH patients matched for BMI and insulin resistance with obese individuals without NASH. No qualitative or quantitative differences in fasting plasma bile acids were found in NASH patients, with only GCA weakly correlating with steatosis (r ¼ 0.29, p ¼ 0.03). However, reanalysis by severity of insulin resistance revealed a tendency toward previously reported associations in fasting plasma bile acids (Table 1 ). These findings suggest that bile acid metabolism correlates with the metabolic comorbidities of NAFLD, rather than with the histopathological parameters of NASH itself [39 & ]. It will be important in future studies to carefully assess NASH independently of common comorbidities to determine which changes, if any, in bile acid metabolism are specifically related to histological changes in NASH.
ARE BILE ACID CHANGES ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE INDEPENDENTLY FROM OBESITY, INSULIN RESISTANCE, AND TYPE 2 DIABETES?
Assessment of the clinicobiological status of the studied populations appears essential to understand discordant results and allow their appropriate interpretation. In studies lacking information on the nutritional status [34, 38, 40] [31, 32] . As discussed above, these metabolic comorbidities of NAFLD are correlated with bile acid alterations. It is thus difficult to conclude whether bile acid alterations are associated per se with NAFLD or with the associated insulin resistance. Appropriate statistical adjustment or patient matching could help to determine whether the associations are independent from potential confounding factors.
CONCLUSION
Although bile acid signaling targets are attractive candidates for the treatment of NAFLD, it remains undetermined whether bile acids are a driving force in the pathogenesis and progression of NAFLD or just innocuous bystanders. The current literature does not clearly support a causal role. Moreover, the large interindividual variation and diurnal bile acid changes in peripheral blood suggest that they are likely unsuitable as biomarkers for the diagnosis or leading to the decision of biopsy taking in NAFLD patients. However, this does not exclude that targeting bile acid signaling remains an attractive therapeutic target for NASH treatment. Further clinical studies assessing plasma bile acid profiles should carefully consider matching BMI and insulin resistance profiles across controls, NAFL, and NASH patients to more clearly assess the connection between alterations in bile acid metabolism and these parameters of the metabolic syndrome.
